News stories about Rockwell Medical (NASDAQ:RMTI) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rockwell Medical earned a news impact score of 0.06 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.7091301707382 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
RMTI has been the subject of several research reports. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. BidaskClub downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Thursday.
Rockwell Medical (NASDAQ:RMTI) traded down $0.06 during midday trading on Thursday, reaching $5.81. 220,406 shares of the company traded hands, compared to its average volume of 327,055. Rockwell Medical has a twelve month low of $5.06 and a twelve month high of $8.98. The firm has a market cap of $303.84, a P/E ratio of -13.50 and a beta of 2.02.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.